Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on June 23, 2025
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
GlobeNewswire
·
June 23, 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment …
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
GlobeNewswire
·
June 23, 2025
Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
GlobeNewswire
·
June 23, 2025
A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“ …
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
GlobeNewswire
·
June 23, 2025
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the …
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
GlobeNewswire
·
June 23, 2025
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce …
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
GlobeNewswire
·
June 23, 2025
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: …
CorMedix inc. Announces Customer Implementation
GlobeNewswire
·
June 23, 2025
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update …
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
GlobeNewswire
·
June 23, 2025
Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseases OrthoCellix is …
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
GlobeNewswire
·
June 23, 2025
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
GlobeNewswire
·
June 23, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label …
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
GlobeNewswire
·
June 23, 2025
Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating …
OXB completes acquisition of remaining stake in US subsidiary
GlobeNewswire
·
June 23, 2025
OXB completes acquisition of remaining stake in US subsidiary Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a …
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
GlobeNewswire
·
June 23, 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed …
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
June 23, 2025
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor …
New DoseSpot Analysis of 100,000 GLP-1 Prescriptions Finds That Patients Overpaid by $10.2M Collectively
GlobeNewswire
·
June 23, 2025
BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today the results of a new data analysis on 102,166 GLP-1 …
Elevate Your Summer with Canada’s Leading Cannabis Brands and Products by Tilray Brands
GlobeNewswire
·
June 23, 2025
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, announces its 2025 summer cannabis …
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
GlobeNewswire
·
June 23, 2025
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, …
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
GlobeNewswire
·
June 23, 2025
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months …
Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan
GlobeNewswire
·
June 23, 2025
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that it has out-licensed its biomarker-guided DB104 (liafensine) program to one of Taiwan’s …
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 23, 2025
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of …